Studies have suggested that metformin suppresses inflammation in diabetes and intestinal inflammation by inhibiting the activity of NF-κB via AMPK-independent and AMPK-dependent processes [52–55]. The gene discussed is PRKAA1; the disease is diabetes mellitus.